Neutral sphingomyelinase-2 and cardiometabolic diseases

Area of Science:

• Biochemistry
• Molecular Biology
• Pathophysiology

Background:

• Sphingolipids, particularly ceramides, are implicated in metabolic syndrome pathologies.
• Neutral sphingomyelinase 2 (nSMase2) dysregulation is linked to inflammation-related diseases.
• Ceramides are produced via sphingomyelin hydrolysis, with nSMase2 playing a key role.

Purpose of the Study:

• To review the biochemistry of nSMase2 and ceramide production.
• To explore nSMase2 regulation by inflammatory cytokines.
• To discuss nSMase2's role in cardiometabolic diseases and potential therapeutic inhibition.

Main Methods:

• Literature review of nSMase2 biochemistry and function.
• Analysis of molecular interactions between nSMase2, ceramides, and cytokines.
• Discussion of existing knowledge on nSMase2 in disease pathogenesis.

Main Results:

• nSMase2 activation by inflammatory cytokines (e.g., TNF-α, IL-1ß) leads to ceramide production.
• Ceramides, in turn, stimulate further inflammatory cytokine release, creating a feed-forward loop.
• This interaction is central to inflammation-driven pathologies in cardiometabolic diseases.

Conclusions:

• nSMase2 is a critical mediator in the inflammatory cycle of cardiometabolic diseases.
• Targeting nSMase2 presents a potential therapeutic strategy against inflammation-driven conditions.
• Understanding the nSMase2-ceramide-cytokine axis is key for developing new treatments.